AveXis’ (NASDAQ:AVXS) Hold Rating Reiterated at Royal Bank Of Canada

AveXis, Inc. (NASDAQ:AVXS)‘s stock had its “hold” rating reiterated by analysts at Royal Bank Of Canada in a report released on Thursday, November 2nd. They presently have a $92.00 price objective on the stock. Royal Bank Of Canada’s price target would indicate a potential downside of 4.16% from the company’s previous close.

Other research analysts have also recently issued research reports about the stock. Zacks Investment Research raised shares of AveXis from a “sell” rating to a “hold” rating in a report on Thursday, July 13th. Sanford C. Bernstein began coverage on shares of AveXis in a research note on Thursday, July 27th. They set an “outperform” rating and a $108.00 target price for the company. Morgan Stanley began coverage on shares of AveXis in a research note on Thursday, August 3rd. They set an “overweight” rating and a $118.00 target price for the company. BMO Capital Markets reissued a “buy” rating and set a $123.00 target price on shares of AveXis in a research note on Friday, August 11th. Finally, Chardan Capital reissued a “buy” rating and set a $130.00 target price (up previously from $102.50) on shares of AveXis in a research note on Friday, August 11th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and thirteen have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $110.67.

AveXis (NASDAQ AVXS) opened at $95.99 on Thursday. AveXis has a 1-year low of $44.68 and a 1-year high of $108.27.

AveXis (NASDAQ:AVXS) last posted its quarterly earnings data on Thursday, November 9th. The company reported ($1.52) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.48) by ($0.04). During the same period last year, the business posted ($0.87) EPS. equities analysts anticipate that AveXis will post -6.23 earnings per share for the current fiscal year.

WARNING: This piece was first published by BBNS and is the property of of BBNS. If you are viewing this piece on another site, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://baseballnewssource.com/markets/avexis-inc-avxs-given-hold-rating-at-royal-bank-of-canada/1753210.html.

In other AveXis news, insider Brian K. Kaspar sold 15,000 shares of the stock in a transaction that occurred on Monday, October 9th. The shares were sold at an average price of $101.46, for a total transaction of $1,521,900.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Sukumar Nagendran sold 1,780 shares of the stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $93.25, for a total transaction of $165,985.00. Following the sale, the vice president now owns 1,780 shares in the company, valued at $165,985. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 35,340 shares of company stock worth $3,559,683. Company insiders own 18.60% of the company’s stock.

Several large investors have recently made changes to their positions in the business. FMR LLC increased its position in shares of AveXis by 13.1% in the 2nd quarter. FMR LLC now owns 4,705,433 shares of the company’s stock valued at $386,598,000 after purchasing an additional 544,475 shares during the last quarter. BlackRock Inc. grew its position in shares of AveXis by 34.7% in the 2nd quarter. BlackRock Inc. now owns 2,301,229 shares of the company’s stock valued at $189,069,000 after buying an additional 592,843 shares during the last quarter. Vanguard Group Inc. grew its position in shares of AveXis by 31.8% in the 2nd quarter. Vanguard Group Inc. now owns 1,575,205 shares of the company’s stock valued at $129,419,000 after buying an additional 380,396 shares during the last quarter. Janus Henderson Group PLC grew its position in shares of AveXis by 52.2% in the 3rd quarter. Janus Henderson Group PLC now owns 1,027,221 shares of the company’s stock valued at $99,363,000 after buying an additional 352,456 shares during the last quarter. Finally, State Street Corp grew its position in shares of AveXis by 104.2% in the 2nd quarter. State Street Corp now owns 1,000,001 shares of the company’s stock valued at $82,163,000 after buying an additional 510,189 shares during the last quarter. 94.90% of the stock is currently owned by institutional investors.

AveXis Company Profile

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Analyst Recommendations for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts


Leave a Reply

 
© 2006-2017 BBNS.